Humana (NYSE:HUM) Price Target Increased to $350.00 by Analysts at Citigroup

Humana (NYSE:HUM) had its price objective raised by Citigroup from $340.00 to $350.00 in a research note released on Thursday, Stock Target Advisor reports. Citigroup currently has a buy rating on the insurance provider’s stock.

A number of other analysts have also commented on HUM. UBS Group lifted their price target on Humana from $266.00 to $317.00 and gave the stock a neutral rating in a report on Thursday, August 1st. Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and lifted their price target for the stock from $300.00 to $345.00 in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on Humana from $288.00 to $322.00 and gave the stock an overweight rating in a report on Thursday, August 1st. Piper Jaffray Companies lifted their price target on Humana from $315.00 to $341.00 and gave the stock an overweight rating in a report on Thursday, August 1st. Finally, Canaccord Genuity reiterated a buy rating on shares of Humana in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Humana currently has an average rating of Buy and a consensus target price of $322.63.

Humana stock traded up $2.44 during mid-day trading on Thursday, reaching $317.58. 1,173,375 shares of the company’s stock were exchanged, compared to its average volume of 1,220,728. The business’s fifty day simple moving average is $277.48 and its 200 day simple moving average is $270.93. The firm has a market capitalization of $39.82 billion, a PE ratio of 21.83, a P/E/G ratio of 1.27 and a beta of 0.85. Humana has a one year low of $225.65 and a one year high of $342.03. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, topping the Zacks’ consensus estimate of $4.58 by $0.45. The business had revenue of $16.24 billion for the quarter, compared to analyst estimates of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. Humana’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company posted $4.58 earnings per share. On average, sell-side analysts forecast that Humana will post 17.75 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. Humana’s payout ratio is presently 15.12%.

In other Humana news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares in the company, valued at $3,764,361.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.54% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC boosted its holdings in shares of Humana by 3.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,871 shares of the insurance provider’s stock worth $762,000 after purchasing an additional 98 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Humana during the 2nd quarter valued at $185,000. Morgan Stanley boosted its stake in Humana by 16.2% during the 2nd quarter. Morgan Stanley now owns 289,736 shares of the insurance provider’s stock valued at $76,866,000 after purchasing an additional 40,376 shares during the last quarter. California Public Employees Retirement System boosted its stake in Humana by 8.6% during the 3rd quarter. California Public Employees Retirement System now owns 850,334 shares of the insurance provider’s stock valued at $217,405,000 after purchasing an additional 67,252 shares during the last quarter. Finally, Advisor Group Inc. boosted its stake in Humana by 8.3% during the 2nd quarter. Advisor Group Inc. now owns 4,913 shares of the insurance provider’s stock valued at $1,303,000 after purchasing an additional 377 shares during the last quarter. Institutional investors own 92.93% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: How Do Mutual Funds Work?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.